Showing 4421-4430 of 5957 results for "".
- Moria Expands its Footprint into Eye Surgery by Acquiring Alchimia SRLhttps://modernod.com/news/moria-expands-its-footprint-into-eye-surgery-by-acquiring-alchimia-srl/2481161/France-based Moria has announced the acquisition of Italian-based company Alchimia SRL, a manufacturer of devices for ophthalmic surgery and human tissue banking. Financial terms of the deal were not disclosed. Founded in 1993, Alchimia has 30 years of expertis
- Paladin Phase 4 Study Confirms Iluvien Patients' Reduced Need for Multiple Treatmentshttps://modernod.com/news/paladin-phase-4-study-confirms-iluvien-patients-reduced-need-for-multiple-treatments/2481156/Alimera Sciences announced that post-hoc analyses from the PALADIN phase 4 safety study demonstrate that median treatment frequency in diabetic macular edema (DME) patients treated with the Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg was lower than from patients on other re
- New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)https://modernod.com/news/new-data-reveal-molecular-drivers-of-thyroid-eye-disease-ted-may-remain-activated-in-patients-with-low-clinical-activity-score-cas/2481152/Horizon Therapeutics announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 (IGF-1) in patients with low CAS. These data were presented during the American Academy of Ophthalmology Annual Meeting (
- Schwind Eye-Tech-Solutions Announces Management Changeshttps://modernod.com/news/schwind-eye-tech-solutions-announces-management-changes/2481149/Rolf Schwind, who was serving as CEO of Schwind eye-tech-solutions GmbH, has withdrawn from active leadership of the company, effective October 1, 2022, and joined the Advisory Board. In that capacity he will continue to contribute to the growth of Schwind with his more than 40 years of
- NovaSight Announces FDA 510(K) Clearance of CureSight Digital Therapy for Amblyopiahttps://modernod.com/news/novasight-announces-fda-510k-clearance-of-curesight-digital-therapy-for-amblyopia/2481148/NovaSight announced that the FDA has cleared CureSight, a digital therapy device for amblyopia (lazy eye). CureSight is an eye-tracking-based system aimed for improving visual acuity and stereo acuity by training the visual system to use both eyes simultaneously. The ground-breaking cle
- Kubota Vision Announces Positive Post Hoc Analysis from Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Diseasehttps://modernod.com/news/kubota-vision-announces-positive-post-hoc-analysis-from-phase-3-clinical-trial-of-emixustat-in-patients-with-stargardt-disease/2481147/Kubota Vision announced positive results from a post hoc analysis of the phase 3 clinical trial of the investigational visual cycle modulator emixustat hydrochloride (emixustat) in patients with Stargardt Disease. The primary objective of this study was to determine if emixustat re
- Shore Capital Partners Announces Sale of EyeSouth Partnershttps://modernod.com/news/shore-capital-partners-announces-sale-of-eyesouth-partners/2481146/Shore Capital Partners, a Chicago-based private equity firm, has announced the sale of EyeSouth Partners, an eye care management services organization, to Olympus Partners. Terms of the deal were not disclosed. Shore formed EyeSouth in 2017 with the goal of creating
- New Study Shows People with Glaucoma are at Significant Risk of Alzheimer’s Diseasehttps://modernod.com/news/new-study-shows-people-with-glaucoma-are-at-significant-risk-of-alzheimers-disease/2481142/A large, nationwide study from Taiwan shows that people with a specific type of glaucoma, called normal-tension glaucoma, are at high risk for developing Alzheimer&r
- MYZE Eye Health Focused Digital Platform Launchedhttps://modernod.com/news/myze-eye-health-focused-digital-platform-launched/2481138/MYZE is a eye care engagement platform designed to help identify, treat, and manage dry eyes. It is designed to simplify the burden of dry eye identification and management by enabling “always available” screenings followed by frictionless access to products, servi
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-pavia-trial-of-eyp-1901-for-the-treatment-of-non-proliferative-diabetic-retinopathy/2481131/EyePoint Pharmaceuticals announced that the first patient has been dosed in the phase 2 PAVIA clinical trial of EYP-1901, a potential sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting non-proliferative diabetic retinopathy (NPDR).